Fritextsökning
Innehållstyper
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Samuel Lagercrantz: Framgången kommer efter många misslyckanden
De allra flesta av de idéer och strategier mot covid-19 som man nu jobbar med kommer att gå i stöpet, men det kan räcka med att en enda fungerar, skriver Samuel Lagercrantz.
-
Nytt samarbete för Sprint bioscience
Samarbetar med LG Chem för att utveckla nya behandlingar för NASH och metabola sjukdomar.
-
Orion cuts 205 jobs
The Finnish company Orion has completed its statutory negotiations. By this, personnel will be reduced by about 205 in Finland.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
Grönt ljus för Hamlet – startar klinisk studie
Fritt fram för klinisk studie med bröstmjölksprotein mot blåscancer.
-
Bring talent to those in need
Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.
-
Swedish nanotech crosses the Atlantic
Genovis signs distribution agreement Finnzymes in US.
-
VD:n om att bygga världsföretag: ”Utveckla inte läkemedel för Nobelpris”
För att bygga ett medicinskt företag i världsklass krävs fyra grundelement, enligt Ascelia Pharmas vd Magnus Corfitzen. – Tre av dem blir ni inte överraskade av...
-
Young, bright and committed to labtech
Ghazal Voghoui recently bought her first apartment and finally settled in Stockholm again. Last year, she finished her law studies and she is relieved to be bac...
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at app...
-
Inga svenska företag i topp 50
Varje år sammanställer Boston Consulting Group en lista över världens 50 mest innovativa företag. Inga svenska företag finns representerade på årets lista som t...
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be ...
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Tom Britton: ”Nivån för flockimmunitet är lägre än vad vi trott”
Nya matematiska modeller pekar på att flockimmunitetsnivån är kraftigt lägre än vad man tidigare trott, och att immuniteten i dagsläget spelar en större roll, e...
-
Dako appoints new CEO
The Danish cancer therapeutic company Dako has appointed a new CEO after Patrik Dahlén.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and on...
-
Top modern lab to Sahlgrenska
The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.
-
New nanotech professor to DTU
The Danish University of Technology, DTU, has appointed Kristoffer Almdal as professor to DTU Nanotech.
-
Travelling scholarship to DTU professor
The Vera og Carl Johan Michaelsens Rejselegat has the founder of the Medicine and Technology program at DTU with a scholarship.
-
New influenza vaccine to EU
The Astrazeneca subsidary Medimmune submits marketing authorisationapplication in EU for an new intranasal vaccine against influenza.
-
Meda gets access to Asia
The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.